Other thrombolytic agents include lenoteplase,
tenecteplase, and reteplase, but the most commonly used drug today is rtPA.
Currently, there are 3 FDA-approved recombinant tissue plasminogen medications: activase (Activase),
tenecteplase (TNKase or "TNK"), and reteplase (Retavase).
Campbell, Ph.D., from the Melbourne Brain Centre in Australia, and colleagues randomized 202 patients with ischemic stroke who had occlusion of the internal carotid, basilar, or middle cerebral artery, and who were eligible for thrombectomy, to receive
tenecteplase (101 patients) or alteplase (101 patients) within 4.5 hours after symptom onset.
Tenecteplase, Adjuvant Medication as per Physician's instructions.
Thrombolysis is a treatment that includes the injection of a clot-busting drug such as alteplase and
tenecteplase. These medications do carry a higher risk of bleeding, however, and can only be administered under certain circumstances.
Tenecteplase (TNK-tPA) is a mutant form of t-PA that has a longer half-life.
The more commonly administered thrombolytic agents fall under the classification of fibrin-specific thrombolytic agents, which include tissue plasminogen activators (t-PA), alteplase (Activase[R]), reteplase (Retavase[R]), and
tenecteplase (TNKase[R]) (Vaishnavi et al., 2011).
(7) Alternatives would be urokinase, streptokinase and
tenecteplase.
Tenecteplase, a genetically engineered mutant tissue plasminogen activator, with prolonged plasma half life and higher fibrin selectivity, has emerged as a promising alternative intravenous alteplase.
This report describes a rare case of splenic rupture following the administration of
Tenecteplase for an inferior myocardial infarction.